Browne L Daniel
CEO and President at Revance Therapeutics, Inc.
- Sold, on record
- $4.2M
- Dollars the filings state
- Form 4 sales
- 14
- Latest Mar 18, 2019
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Revance Therapeutics, Inc.CEO and President
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Revance Therapeutics, Inc.Plan not statedAug 23 2017
Sold 22,800 shares at $22.76 ($519k)
Browne L Daniel, CEO and President
Sold 12.7% of holdings ($4.1M position)156,050 shares left1.9x usual sizeFiling
- 2 Form 4 sale Revance Therapeutics, Inc.Plan not statedSep 20 +28 days
Sold 7,600 shares at $23.58 ($179k)
Browne L Daniel, CEO and President
Sold 4.9% of holdings ($3.7M position)148,450 shares left0.6x usual sizeFiling
- 3 Form 4 sale Revance Therapeutics, Inc.Plan not statedOct 18 +28 days
Sold 7,662 shares at $26.16 ($200k)
Browne L Daniel, CEO and President
Sold 5.2% of holdings ($3.9M position)140,788 shares left0.6x usual sizeFiling
- 4 Form 4 sale Revance Therapeutics, Inc.Plan not statedNov 22 +35 days
Sold 7,600 shares at $24.94 ($190k)
Browne L Daniel, CEO and President
Sold 5.4% of holdings ($3.5M position)133,188 shares left0.6x usual sizeFiling
- 5 Form 4 sale Revance Therapeutics, Inc.Plan not statedMar 7 +105 days
Sold 27,283 shares at $31.43 ($858k)
Browne L Daniel, CEO and President
Sold 17.2% of holdings ($5M position)131,208 shares left2.3x usual sizeFiling
- 6 Form 4 sale Revance Therapeutics, Inc.Plan not statedMar 16 +9 days
Sold 6,452 shares at $31.64 ($204k)
Browne L Daniel, CEO and President
Sold 4.3% of holdings ($4.7M position)141,875 shares left0.5x usual sizeFiling
- 7 Form 4 sale Revance Therapeutics, Inc.Plan not statedFeb 19 +340 days
Sold 5,446 shares at $17.68 ($96k)
Browne L Daniel, CEO and President
Sold 3.1% of holdings ($3.1M position)168,943 shares left0.6x usual sizeFiling
- 8 Form 4 sale Revance Therapeutics, Inc.Plan not statedMar 18 +27 days
Sold 11,613 shares at $15.51 ($180k)
Browne L Daniel, CEO and President
Sold 7.1% of holdings ($2.5M position)151,193 shares left1.5x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (14)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2019 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 11,613 | $180k | 7.1% | Plan not stated | SEC |
| Feb 19, 2019 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 5,446 | $96k | 3.1% | Plan not stated | SEC |
| Mar 16, 2018 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 6,452 | $204k | 4.3% | Plan not stated | SEC |
| Mar 7, 2018 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 27,283 | $858k | 17.2% | Plan not stated | SEC |
| Nov 22, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 7,600 | $190k | 5.4% | Plan not stated | SEC |
| Oct 18, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 7,662 | $200k | 5.2% | Plan not stated | SEC |
| Sep 20, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 7,600 | $179k | 4.9% | Plan not stated | SEC |
| Aug 23, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 22,800 | $519k | 12.7% | Plan not stated | SEC |
| May 24, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 32,000 | $649k | 16.3% | Plan not stated | SEC |
| Feb 22, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 11,037 | $227k | 5.2% | Plan not stated | SEC |
| Jan 25, 2017 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 12,000 | $237k | 6.1% | Plan not stated | SEC |
| Dec 28, 2016 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 12,000 | $251k | 5.8% | Plan not stated | SEC |
| Nov 25, 2016 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 12,000 | $215k | 5.5% | Plan not stated | SEC |
| Oct 26, 2016 | Revance Therapeutics, Inc. | CEO and President | Form 4 sale | 12,000 | $178k | 5.2% | Plan not stated | SEC |